<?xml version="1.0" encoding="UTF-8"?>
<p>Inclusion/exclusion criteria were similar to those in the original oral NEPA pivotal trials [
 <xref rid="mdx698-B12" ref-type="bibr">12</xref>, 
 <xref rid="mdx698-B13" ref-type="bibr">13</xref>, 
 <xref rid="mdx698-B15" ref-type="bibr">15</xref>]. Eligible patients were ≥18 years, naïve to chemotherapy, and scheduled to receive their first course of cisplatin-based (≥50 mg/m
 <sup>2</sup>) chemotherapy (as monotherapy or in combination with other chemotherapy) for the treatment of a confirmed solid tumor malignancy. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0–2.
</p>
